Proteomic profiling of cerebrospinal fluid in Creutzfeldt-Jakob disease

Expert Review of Proteomics

Volumn 7, Issue 6, 2010, Pages 907-917

  Qualtieri, Antonio ^a   Urso, Elena ^a   Pera, Maria Le ^a   Sprovieri, Teresa ^a   Bossio, Sabrina ^b   Gambardella, Antonio ^a,c   Quattrone, Aldo ^c,d  

^a INSTITUTE OF NEUROLOGICAL SCIENCES   (Italy)

^b Azienda Ospedaliera Cosenza   (Italy)

^c UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

^d CNR   (Italy)

Author keywords

cerebrospinal fluid; Creutzfeldt Jakob disease; MALDI TOF profiling; prion protein; proteome

Indexed keywords

BIOLOGICAL MARKER; PRION PROTEIN;

AUTOPSY; CEREBROSPINAL FLUID ANALYSIS; CREUTZFELDT JAKOB DISEASE; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE ACTIVITY; DISEASE COURSE; ENZYME LINKED IMMUNOSORBENT ASSAY; HISTOPATHOLOGY; HUMAN; NERVE CELL; NERVE DEGENERATION; NONHUMAN; PRION DISEASE; PROTEIN ANALYSIS; PROTEIN CONFORMATION; PROTEIN STRUCTURE; PROTEOMICS; REVIEW; SURFACE ENHANCED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; TWO DIMENSIONAL ELECTROPHORESIS; WESTERN BLOTTING;

ANIMALS; BIOLOGICAL MARKERS; CEREBROSPINAL FLUID; CREUTZFELDT-JAKOB SYNDROME; HUMANS; PROTEOME; PROTEOMICS;

EID: 78650461840     PISSN: 14789450     EISSN: 17448387     Source Type: Journal    
DOI: 10.1586/epr.10.80     Document Type: Review

References (158)

1. Van Everbroeck B, Pals P, Quoilin S, Martin JJ, Cras P. The many faces of human prion diseases in Belgium and the world. Acta Neurol. Belg. 101(2), 81-87 (2001). (Pubitemid 33607002)
2. Hill AF, Joiner S, Wadsworth JD et al. Molecular classification of sporadic Creutzfeldt-Jakob disease. Brain 126(Pt 6), 1333-1346 (2003). (Pubitemid 36644379)
3. Parchi P, Giese A, Capellari S et al. Classification of sporadic Creutzfeldt-Jakob disease based on molecular and phenotypic analysis of 300 subjects. Ann. Neurol. 46(2), 224-233 (1999). (Pubitemid 29382879)
4. Masters CL, Harris JO, Gajdusek DC et al. Creutzfeldt-Jakob disease: patterns of worldwide occurrence and the significance of familial and sporadic clustering. Ann. Neurol. 5(2), 177-188 (1979).
5. Goldfarb LG, Korczyn AD, Brown P, Chapman J, Gajdusek DC. Mutation in codon 200 of scrapie amyloid precursor gene linked to Creutzfeldt-Jakob disease in Sephardic Jews of Libyan and non-Libyan origin. Lancet 336(8715), 637-638 (1990). (Pubitemid 20296976)
6. Kovacs GG, Trabattoni G, Hainfellner JA et al. Mutations of the prion protein gene phenotypic spectrum. J. Neurol. 249(11), 1567-1582 (2002). (Pubitemid 35477900)
7. Hill AF, Desbruslais M, Joiner S et al. The same prion strain causes vCJD and BSE. Nature 389(6650), 448-450, 526 (1997). (Pubitemid 27435311)
8. Will RG, Ironside JW, Zeidler M et al. A new variant of Creutzfeldt-Jakob disease in the UK. Lancet 347(9006), 921-925 (1996). (Pubitemid 26102546)
9. Brown P, Brandel JP, Preece M, Sato T. Iatrogenic Creutzfeldt-Jakob disease: the waning of an era. Neurology 67(3), 389-393 (2006). (Pubitemid 44214958)
10. Brown P, Preece M, Brandel JP et al. Iatrogenic Creutzfeldt-Jakob disease at the millennium. Neurology 55(8), 1075-1081 (2000).
11. Llewelyn CA, Hewitt PE, Knight RS et al. Possible transmission of variant Creutzfeldt- Jakob disease by blood transfusion. Lancet 363(9407), 417-421 (2004). (Pubitemid 38210057)
12. Gajdusek DC. Unconventional viruses and the origin and disappearance of kuru. Science 197(4307), 943-960 (1977).
13. Williams ES, Young S. Chronic wasting disease of captive mule deer: a spongiform encephalopathy. J. Wildl. Dis. 16(1), 89-98 (1980).
14. Spraker TR, Miller MW, Williams ES et al. Spongiform encephalopathy in free-ranging mule deer (Odocoileus hemionus), white-tailed deer (Odocoileus virginianus) and Rocky Mountain elk (Cervus elaphus nelsoni) in north central Colorado. J. Wildl. Dis. 33(1), 1-6 (1997).
15. Xie Z, ORourke KI, Dong Z et al. Chronic wasting disease of elk and deer and Creutzfeldt-Jakob disease: comparative analysis of the scrapie prion protein. J. Biol. Chem. 281(7), 4199-4206 (2006). (Pubitemid 43847848)
16. Lopez Garcia F, Zahn R, Riek R, Wuthrich K. NMR structure of the bovine prion protein. Proc. Natl Acad. Sci. USA 97(15), 8334-8339 (2000). (Pubitemid 30639673)
17. Riek R, Hornemann S, Wider G et al. NMR structure of the mouse prion protein domain PrP(121-321). Nature 382(6587), 180-182 (1996). (Pubitemid 26242887)
18. Harris DA. Cellular biology of prion diseases. Clin. Microbiol. Rev. 12(3), 429-444 (1999).
19. Capellari S, Parchi P, Russo CM et al. Effect of the E200K mutation on prion protein metabolism. Comparative study of a cell model and human brain. Am. J. Pathol. 157(2), 613-622 (2000). (Pubitemid 30626920)
20. Petersen RB, Parchi P, Richardson SL, Urig CB, Gambetti P. Effect of the D178N mutation and the codon 129 polymorphism on the metabolism of the prion protein. J. Biol. Chem. 271(21), 12661-12668 (1996). (Pubitemid 26160942)
21. Aguzzi A. Cell biology: beyond the prion principle. Nature 459(7249), 924-925 (2009).
22. Castilla J, Saa P, Hetz C, Soto C. In vitro generation of infectious scrapie prions. Cell 121(2), 195-206 (2005). (Pubitemid 40546388)
23. Sigurdson CJ, Nilsson KP, Hornemann S et al. De novo generation of a transmissible spongiform encephalopathy by mouse transgenesis. Proc. Natl Acad. Sci. USA 106(1), 304-309 (2009).
24. Brandner S, Isenmann S, Raeber A et al. Normal host prion protein necessary for scrapie-induced neurotoxicity. Nature 379(6563), 339-343 (1996). (Pubitemid 26033075)
25. Mallucci G, Dickinson A, Linehan J et al. Depleting neuronal PrP in prion infection prevents disease and reverses spongiosis. Science 302(5646), 871-874 (2003). (Pubitemid 37339628)
26. Chesebro B, Trifilo M, Race R et al. Anchorless prion protein results in infectious amyloid disease without clinical scrapie. Science 308(5727), 1435-1439 (2005). (Pubitemid 40791292)
27. Gorodinsky A, Harris DA. Glycolipid-anchored proteins in neuroblastoma cells form detergent-resistant complexes without caveolin. J. Cell. Biol. 129(3), 619-627 (1995).
28. Vey M, Pilkuhn S, Wille H et al. Subcellular colocalization of the cellular and scrapie prion proteins in caveolae-like membranous domains. Proc. Natl Acad. Sci. USA 93(25), 14945-14949 (1996). (Pubitemid 26419075)
29. Naslavsky N, Stein R, Yanai A, Friedlander G, Taraboulos A. Characterization of detergent-insoluble complexes containing the cellular prion protein and its scrapie isoform. J. Biol. Chem. 272(10), 6324-6331 (1997). (Pubitemid 27118107)
30. Shyng SL, Heuser JE, Harris DA. A glycolipid-anchored prion protein is endocytosed via clathrin-coated pits. J. Cell. Biol. 125(6), 1239-1250 (1994).
31. Pauly PC, Harris DA. Copper stimulates endocytosis of the prion protein. J. Biol. Chem. 273(50), 33107-33110 (1998). (Pubitemid 29005676)
32. Sakaguchi S, Katamine S, Nishida N et al. Loss of cerebellar Purkinje cells in aged mice homozygous for a disrupted PrP gene. Nature 380(6574), 528-531 (1996). (Pubitemid 26110641)
33. Tobler I, Gaus SE, Deboer T et al. Altered circadian activity rhythms and sleep in mice devoid of prion protein. Nature 380(6575), 639-642 (1996). (Pubitemid 26119019)
34. Moore RC, Mastrangelo P, Bouzamondo E et al. Doppel-induced cerebellar degeneration in transgenic mice. Proc. Natl Acad. Sci. USA 98(26), 15288-15293 (2001). (Pubitemid 34014007)
35. Lauren J, Gimbel DA, Nygaard HB, Gilbert JW, Strittmatter SM. Cellular prion protein mediates impairment of synaptic plasticity by amyloid-b oligomers. Nature 457(7233), 1128-1132 (2009).
36. Cisse M, Mucke L. Alzheimers disease: a prion protein connection. Nature 457(7233), 1090-1091 (2009).
37. Li R, Liu D, Zanusso G et al. The expression and potential function of cellular prion protein in human lymphocytes. Cell. Immunol. 207(1), 49-58 (2001). (Pubitemid 32165792)
38. Dodelet VC, Cashman NR. Prion protein expression in human leukocyte differentiation. Blood 91(5), 1556-1561 (1998). (Pubitemid 28110319)
39. Durig J, Giese A, Schulz-Schaeffer W et al. Differential constitutive and activation-dependent expression of prion protein in human peripheral blood leucocytes. Br. J. Haematol. 108(3), 488-495 (2000). (Pubitemid 30196243)
40. Aguzzi A, Heikenwalder M. Prions, cytokines, and chemokines: a meeting in lymphoid organs. Immunity 22(2), 145-154 (2005). (Pubitemid 40255706)
41. Aguzzi A. Peripheral prion pursuit. J. Clin. Invest. 108(5), 661-662 (2001). (Pubitemid 32906192)
42. Bruce ME, McConnell I, Will RG, Ironside JW. Detection of variant Creutzfeldt-Jakob disease infectivity in extraneural tissues. Lancet 358(9277), 208-209 (2001). (Pubitemid 32718547)
43. Glatzel M, Abela E, Maissen M, Aguzzi A. Extraneural pathologic prion protein in sporadic Creutzfeldt-Jakob disease. N. Engl. J. Med. 349(19), 1812-1820 (2003). (Pubitemid 37362957)
44. Mabbott NA, Bruce ME. Prion disease: bridging the spleen-nerve gap. Nat. Med. 9(12), 1463-1464 (2003).
45. Sigurdson CJ, Barillas-Mury C, Miller MW et al. PrP(CWD) lymphoid cell targets in early and advanced chronic wasting disease of mule deer. J. Gen. Virol. 83(Pt 10), 2617-2628 (2002).
46. Cole S, Kimberlin RH. Pathogenesis of mouse scrapie: dynamics of vacuolation in brain and spinal cord after intraperitoneal infection. Neuropathol. Appl. Neurobiol. 11(3), 213-227 (1985). (Pubitemid 15059499)
47. McBride PA, Beekes M. Pathological PrP is abundant in sympathetic and sensory ganglia of hamsters fed with scrapie. Neurosci. Lett. 265(2), 135-138 (1999). (Pubitemid 29210387)
48. Haik S, Faucheux BA, Sazdovitch V et al. The sympathetic nervous system is involved in variant Creutzfeldt-Jakob disease. Nat. Med. 9(9), 1121-1123 (2003). (Pubitemid 37173693)
49. Beekes M, McBride PA. The spread of prions through the body in naturally acquired transmissible spongiform encephalopathies. FEBS J. 274(3), 588-605 (2007). (Pubitemid 46150854)
50. Mabbott NA, MacPherson GG. Prions and their lethal journey to the brain. Nat. Rev. Microbiol. 4(3), 201-211 (2006).
51. Nuvolone M, Aguzzi A, Heikenwalder M. Cells and prions: a license to replicate. FEBS Lett. 583(16), 2674-2684 (2009).
52. Ma J, Wollmann R, Lindquist S. Neurotoxicity and neurodegeneration when PrP accumulates in the cytosol. Science 298(5599), 1781-1785 (2002). (Pubitemid 35404120)
53. Grenier C, Bissonnette C, Volkov L, Roucou X. Molecular morphology and toxicity of cytoplasmic prion protein aggregates in neuronal and non-neuronal cells. J. Neurochem. 97(5), 1456-1466 (2006). (Pubitemid 43725584)
54. Wang X, Wang F, Arterburn L, Wollmann R, Ma J. The interaction between cytoplasmic prion protein and the hydrophobic lipid core of membrane correlates with neurotoxicity. J. Biol. Chem. 281(19), 13559-13565 (2006). (Pubitemid 43855269)
55. Fioriti L, Dossena S, Stewart LR et al. Cytosolic prion protein (PrP) is not toxic in N2a cells and primary neurons expressing pathogenic PrP mutations. J. Biol. Chem. 280(12), 11320-11328 (2005). (Pubitemid 40418439)
56. Roucou X, Guo Q, Zhang Y, Goodyer CG, LeBlanc AC. Cytosolic prion protein is not toxic and protects against Bax-mediated cell death in human primary neurons. J. Biol. Chem. 278(42), 40877-40881 (2003). (Pubitemid 37280906)
57. Kovacs GG, Budka H. Prion diseases: from protein to cell pathology. Am. J. Pathol. 172(3), 555-565 (2008). (Pubitemid 351354529)
58. Meissner B, Westner IM, Kallenberg K et al. Sporadic Creutzfeldt-Jakob disease: clinical and diagnostic characteristics of the rare VV1 type. Neurology 65(10), 1544-1550 (2005). (Pubitemid 41689466)
59. Collins SJ, Sanchez-Juan P, Masters CL et al. Determinants of diagnostic investigation sensitivities across the clinical spectrum of sporadic Creutzfeldt-Jakob disease. Brain 129(Pt 9), 2278-2287 (2006). (Pubitemid 44522114)
60. Krasnianski A, Schulz-Schaeffer WJ, Kallenberg K et al. Clinical findings and diagnostic tests in the MV2 subtype of sporadic CJD. Brain 129(Pt 9), 2288-2296 (2006). (Pubitemid 44522115)
61. Wieser HG, Schindler K, Zumsteg D. EEG in Creutzfeldt-Jakob disease. Clin. Neurophysiol. 117(5), 935-951 (2006).
62. Hsich G, Kenney K, Gibbs CJ, Lee KH, Harrington MG. The 14-3-3 brain protein in cerebrospinal fluid as a marker for transmissible spongiform encephalopathies. N. Engl. J. Med. 335(13), 924-930 (1996). (Pubitemid 26314445)
63. Zerr I, Bodemer M, Gefeller O et al. Detection of 14-3-3 protein in the cerebrospinal fluid supports the diagnosis of Creutzfeldt-Jakob disease. Ann. Neurol. 43(1), 32-40 (1998). (Pubitemid 28124646)
64. Kenney K, Brechtel C, Takahashi H et al. An enzyme-linked immunosorbent assay to quantify 14-3-3 proteins in the cerebrospinal fluid of suspected Creutzfeldt-Jakob disease patients. Ann. Neurol. 48(3), 395-398 (2000).
65. Aksamit AJ Jr, Preissner CM, Homburger HA. Quantitation of 14-3-3 and neuron-specific enolase proteins in CSF in Creutzfeldt-Jakob disease. Neurology 57(4), 728-730 (2001). (Pubitemid 32783012)
66. Green AJ. Use of 14-3-3 in the diagnosis of Creutzfeldt-Jakob disease. Biochem. Soc. Trans. 30(4), 382-386 (2002). (Pubitemid 35001561)
67. Geschwind MD, Martindale J, Miller D et al. Challenging the clinical utility of the 14-3-3 protein for the diagnosis of sporadic Creutzfeldt-Jakob disease. Arch. Neurol. 60(6), 813-816 (2003). (Pubitemid 36705966)
68. Sanchez-Juan P, Green A, Ladogana A et al. CSF tests in the differential diagnosis of Creutzfeldt-Jakob disease. Neurology 67(4), 637-643 (2006). (Pubitemid 44273611)
69. Gmitterova K, Heinemann U, Bodemer M et al. 14-3-3 CSF levels in sporadic Creutzfeldt-Jakob disease differ across molecular subtypes. Neurobiol. Aging 30(11), 1842-1850 (2009).
70. Van Everbroeck B, Dobbeleir I, De Waele M et al. Differential diagnosis of 201 possible Creutzfeldt-Jakob disease patients. J. Neurol. 251(3), 298-304 (2004). (Pubitemid 38387147)
71. Otto M, Wiltfang J, Cepek L et al. Tau protein and 14-3-3 protein in the differential diagnosis of Creutzfeldt-Jakob disease. Neurology 58(2), 192-197 (2002). (Pubitemid 34084207)
72. Otto M, Wiltfang J, Tumani H et al. Elevated levels of tau-protein in cerebrospinal fluid of patients with Creutzfeldt-Jakob disease. Neurosci. Lett. 225(3), 210-212 (1997). (Pubitemid 27191632)
73. Zerr I, Bodemer M, Racker S et al. Cerebrospinal fluid concentration of neuron-specific enolase in diagnosis of Creutzfeldt-Jakob disease. Lancet 345(8965), 1609-1610 (1995).
74. Beaudry P, Cohen P, Brandel JP et al. 14-3-3 protein, neuron-specific enolase, and S-100 protein in cerebrospinal fluid of patients with Creutzfeldt-Jakob disease. Dement. Geriatr. Cogn. Disord. 10(1), 40-46 (1999). (Pubitemid 28567041)
75. Kohira I, Tsuji T, Ishizu H et al. Elevation of neuron-specific enolase in serum and cerebrospinal fluid of early stage Creutzfeldt-Jakob disease. Acta Neurol. Scand. 102(6), 385-387 (2000).
76. Otto M, Stein H, Szudra A et al. S-100 protein concentration in the cerebrospinal fluid of patients with Creutzfeldt-Jakob disease. J. Neurol. 244(9), 566-570 (1997). (Pubitemid 27464102)
77. Jimi T, Wakayama Y, Shibuya S et al. High levels of nervous system-specific proteins in cerebrospinal fluid in patients with early stage Creutzfeldt-Jakob disease. Clin. Chim. Acta 211(1-2), 37-46 (1992).
78. Van Everbroeck B, Green AJ, Pals P, Martin JJ, Cras P. Decreased levels of amyloid-b 1-42 in cerebrospinal fluid of Creutzfeldt-Jakob disease patients. J. Alzheimers Dis. 1(6), 419-424 (1999).
79. Otto M, Esselmann H, Schulz-Shaeffer W et al. Decreased b-amyloid1-42 in cerebrospinal fluid of patients with Creutzfeldt-Jakob disease. Neurology 54(5), 1099-1102 (2000). (Pubitemid 30151852)
80. Human transmissible spongiform encephalopathies. Wkly Epidemiol. Rec. 73(47), 361-365 (1998).
81. Edler J, Mollenhauer B, Heinemann U et al. Movement disturbances in the differential diagnosis of Creutzfeldt-Jakob disease. Mov. Disord. 24(3), 350-356 (2009).
82. Zerr I, Kallenberg K, Summers DM et al. Updated clinical diagnostic criteria for sporadic Creutzfeldt-Jakob disease. Brain 132(Pt 10), 2659-2668 (2009).
83. McGregor E, Dunn MJ. Proteomics of the heart: unraveling disease. Circ. Res. 98(3), 309-321 (2006). (Pubitemid 43755327)
84. Dowling P, Walsh N, Clynes M. Membrane and membrane-associated proteins involved in the aggressive phenotype displayed by highly invasive cancer cells. Proteomics 8(19), 4054-4065 (2008).
85. Roche S, Gabelle A, Lehmann S. Clinical proteomics of the cerebrospinal fluid:towards the discovery of new biomarkers. Proteomics Clin. Appl. 2, 428-436 (2008). (Pubitemid 351425370)
86. Spector R, Johanson CE. The mammalian choroid plexus Am. Sci. 261(5), 68-74 (1989).
87. Yuan X, Desiderio DM. Proteomics analysis of prefractionated human lumbar cerebrospinal fluid. Proteomics 5(2), 541-550 (2005). (Pubitemid 40262071)
88. Sihlbom C, Davidsson P, Nilsson CL. Prefractionation of cerebrospinal fluid to enhance glycoprotein concentration prior to structural determination with FT-ICR mass spectrometry. J. Proteome Res. 4(6), 2294-2301 (2005). (Pubitemid 41814299)
89. Ogata Y, Charlesworth MC, Muddiman DC. Evaluation of protein depletion methods for the analysis of total-, phospho- and glycoproteins in lumbar cerebrospinal fluid. J. Proteome Res. 4(3), 837-845 (2005). (Pubitemid 40863272)
90. Ramstrom M, Zuberovic A, Gronwall C et al. Development of affinity columns for the removal of high-abundance proteins in cerebrospinal fluid. Biotechnol. Appl. Biochem. 52(Pt 2), 159-166 (2009).
91. Portelius E, Westman-Brinkmalm A, Zetterberg H, Blennow K. Determination of b-amyloid peptide signatures in cerebrospinal fluid using immunoprecipitation-mass spectrometry. J. Proteome Res. 5(4), 1010-1016 (2006).
92. You JS, Gelfanova V, Knierman MD et al. The impact of blood contamination on the proteome of cerebrospinal fluid. Proteomics 5(1), 290-296 (2005). (Pubitemid 40189659)
93. Harrington MG, Merril CR. Two-dimensional electrophoresis and ultrasensitive silver staining of cerebrospinal fluid proteins in neurological diseases. Clin. Chem. 30(12 Pt 1), 1933-1937 (1984). (Pubitemid 15079380)
94. Bracco F, Gallo P, Tavolato B, Battistin L. Two-dimensional electrophoresis of cerebrospinal fluid proteins in normal and pathological conditions. Neurochem. Res. 10(9), 1203-1219 (1985). (Pubitemid 15242640)
95. Finehout EJ, Franck Z, Lee KH. Towards two-dimensional electrophoresis mapping of the cerebrospinal fluid proteome from a single individual. Electrophoresis 25(15), 2564-2575 (2004). (Pubitemid 39193667)
96. Dekker LJ, Boogerd W, Stockhammer G et al. MALDI-TOF mass spectrometry analysis of cerebrospinal fluid tryptic peptide profiles to diagnose leptomeningeal metastases in patients with breast cancer. Mol. Cell. Proteomics 4(9), 1341-1349 (2005). (Pubitemid 41448721)
97. Jimenez CR, Koel-Simmelink M, Pham TV, van der Voort L, Teunissen CE. Endogeneous peptide profiling of cerebrospinal fluid by MALDI-TOF mass spectrometry: optimization of magnetic bead-based peptide capture and analysis of preanalytical variables. Proteomics Clin. Appl. 1(11), 1385-1392 (2007).
98. Mohring T, Kellmann M, Jurgens M, Schrader M. Top-down identification of endogenous peptides up to 9 kDa in cerebrospinal fluid and brain tissue by nanoelectrospray quadrupole time-of-flight tandem mass spectrometry. J. Mass Spectrom. 40(2), 214-226 (2005). (Pubitemid 40327261)
99. Carrette O, Demalte I, Scherl A et al. A panel of cerebrospinal fluid potential biomarkers for the diagnosis of Alzheimers disease. Proteomics 3(8), 1486-1494 (2003). (Pubitemid 37048074)
100. Ruetschi U, Zetterberg H, Podust VN et al. Identification of CSF biomarkers for frontotemporal dementia using SELDI-TOF. Exp. Neurol. 196(2), 273-281 (2005). (Pubitemid 41607815)
101. Cottingham K. Clinical proteomics: are we there yet? Anal. Chem. 75(21), 472A-476A (2003). (Pubitemid 37356439)
102. Zougman A, Pilch B, Podtelejnikov A et al. Integrated analysis of the cerebrospinal fluid peptidome and proteome. J. Proteome Res. 7(1), 386-399 (2008). (Pubitemid 351171153)
103. Korolainen MA, Nyman TA, Aittokallio T, Pirttila T. An update on clinical proteomics in Alzheimers research. J. Neurochem. 112(6), 1386-1414 (2010).
104. Zellner M, Veitinger M, Umlauf E. The role of proteomics in dementia and Alzheimers disease. Acta Neuropathol. 118(1), 181-195 (2009).
105. Finehout EJ, Franck Z, Choe LH, Relkin N, Lee KH. Cerebrospinal fluid proteomic biomarkers for Alzheimers disease. Ann. Neurol. 61(2), 120-129 (2007). (Pubitemid 46363839)
106. Davidsson P, Sjogren M, Andreasen N et al. Studies of the pathophysiological mechanisms in frontotemporal dementia by proteome analysis of CSF proteins. Brain Res. Mol. Brain Res. 109(1-2), 128-133 (2002). (Pubitemid 36082878)
107. Hansson SF, Puchades M, Blennow K, Sjogren M, Davidsson P. Validation of a prefractionation method followed by two-dimensional electrophoresis - applied to cerebrospinal fluid proteins from frontotemporal dementia patients. Proteome Sci. 2(1), 7 (2004). (Pubitemid 41630799)
108. Hammack BN, Fung KY, Hunsucker SW et al. Proteomic analysis of multiple sclerosis cerebrospinal fluid. Mult. Scler. 10(3), 245-260 (2004). (Pubitemid 38807450)
109. Lehmensiek V, Sussmuth SD, Tauscher G et al. Cerebrospinal fluid proteome profile in multiple sclerosis. Mult. Scler. 13(7), 840-849 (2007). (Pubitemid 351540854)
110. Ottervald J, Franzen B, Nilsson K et al. Multiple sclerosis: identification and clinical evaluation of novel CSF biomarkers. J. Proteomics 73(6), 1117-1132 (2010).
111. Licker V, Kovari E, Hochstrasser DF, Burkhard PR. Proteomics in human Parkinsons disease research. J. Proteomics 73(1), 10-29 (2009).
112. Abdi F, Quinn JF, Jankovic J et al. Detection of biomarkers with a multiplex quantitative proteomic platform in cerebrospinal fluid of patients with neurodegenerative disorders. J. Alzheimers Dis. 9(3), 293-348 (2006). (Pubitemid 44253348)
113. Schuhmann MU, Zucht HD, Nassimi R et al. Peptide screening of cerebrospinal fluid in patients with glioblastoma multiforme. Eur. J. Surg. Oncol. 36(2), 201-207 (2010).
114. Khwaja FW, Nolen JD, Mendrinos SE et al. Proteomic analysis of cerebrospinal fluid discriminates malignant and nonmalignant disease of the central nervous system and identifies specific protein markers. Proteomics 6(23), 6277-6287 (2006).
115. Yuan X, Desiderio DM. Human cerebrospinal fluid peptidomics. J. Mass Spectrom. 40(2), 176-181 (2005). (Pubitemid 40327257)
116. Elliott MH, Smith DS, Parker CE, Borchers C. Current trends in quantitative proteomics. J. Mass Spectrom. 44(12), 1637-1660 (2009).
117. Oberg AL, Vitek O. Statistical design of quantitative mass spectrometry-based proteomic experiments. J. Proteome Res. 8(5), 2144-2156 (2009).
118. Agrawal GK, Thelen JJ. A high-resolution two dimensional Gel- and Pro-Q DPS-based proteomics workflow for phosphoprotein identification and quantitative profiling. Methods Mol. Biol. 527, 3-19 ix (2009).
119. Urso E, Le Pera M, Bossio S, Sprovieri T, Qualtieri A. Quantification of thymosin b(4) in human cerebrospinal fluid using matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. Anal. Biochem. 402(1), 13-19 (2010).
120. Rifai N, Gillette MA, Carr SA. Protein biomarker discovery and validation: the long and uncertain path to clinical utility. Nat. Biotechnol. 24(8), 971-983 (2006). (Pubitemid 44215392)
121. Mischak H, Apweiler R, Banks RE et al. Clinical proteomics: a need to define the field and to begin to set adequate standards. Proteomics Clin. Appl. 1(2), 148-156 (2007).
122. Peoch K, Beaudry P, Laupretre N, Laplanche JL. CSF detection of the 14-3-3 protein in unselected patients with dementia. Neurology 58(3), 509-510 (2002).
123. Green AJ, Knight RS, Macleod MA, Lowman A, Will RG. Misleading results with the 14-3-3 assay for the diagnosis of Creutzfeldt-Jakob disease. Neurology 56(7), 986-987 (2001).
124. Harrington MG, Merril CR, Asher DM, Gajdusek DC. Abnormal proteins in the cerebrospinal fluid of patients with Creutzfeldt-Jakob disease. N. Engl. J. Med. 315(5), 279-283 (1986).
125. Harrington MG, Merril CR. Cerebrospinal fluid protein analysis in diseases of the nervous system. J. Chromatogr. 429, 345-358 (1988).
126. Zerr I, Bodemer M, Otto M et al. Diagnosis of Creutzfeldt-Jakob disease by two-dimensional gel electrophoresis of cerebrospinal fluid. Lancet 348(9031), 846-849 (1996). (Pubitemid 26320899)
127. Zabel C, Sagi D, Kaindl AM et al. Comparative proteomics in neurodegenerative and non-neurodegenerative diseases suggest nodal point proteins in regulatory networking. J. Proteome Res. 5(8), 1948-1958 (2006). (Pubitemid 44232708)
128. Choe LH, Green A, Knight RS, Thompson EJ, Lee KH. Apolipoprotein E and other cerebrospinal fluid proteins differentiate ante mortem variant Creutzfeldt-Jakob disease from ante mortem sporadic Creutzfeldt-Jakob disease. Electrophoresis 23(14), 2242-2246 (2002). (Pubitemid 34442677)
129. Guillaume E, Zimmermann C, Burkhard PR, Hochstrasser DF, Sanchez JC. A potential cerebrospinal fluid and plasmatic marker for the diagnosis of Creutzfeldt-Jakob disease. Proteomics 3(8), 1495-1499 (2003). (Pubitemid 37048075)
130. Sanchez JC, Guillaume E, Lescuyer P et al. Cystatin C as a potential cerebrospinal fluid marker for the diagnosis of Creutzfeldt-Jakob disease. Proteomics 4(8), 2229-2233 (2004). (Pubitemid 39025322)
131. Carrette O, Burkhard PR, Hughes S, Hochstrasser DF, Sanchez JC. Truncated cystatin C in cerebrospiral fluid: technical [corrected] artefact or biological process? Proteomics 5(12), 3060-3065 (2005). (Pubitemid 41176472)
132. Piubelli C, Fiorini M, Zanusso G et al. Searching for markers of Creutzfeldt-Jakob disease in cerebrospinal fluid by two-dimensional mapping. Proteomics 6(Suppl. 1), S256-S261 (2006).
133. Brechlin P, Jahn O, Steinacker P et al. Cerebrospinal fluid-optimized two-dimensional difference gel electrophoresis (2-D DIGE) facilitates the differential diagnosis of Creutzfeldt-Jakob disease. Proteomics 8(20), 4357-4366 (2008).
134. Cepek L, Brechlin P, Steinacker P et al. Proteomic analysis of the cerebrospinal fluid of patients with Creutzfeldt-Jakob disease. Dement. Geriatr. Cogn. Disord. 23(1), 22-28 (2007). (Pubitemid 46005787)
135. Qualtieri A, Urso E, Le Pera M et al. Thymosin 4 is differentially expressed in the cerebrospinal fluid of Creutzfeldt- Jakob disease patients: a MALDI-TOF MS protein profiling study. Proteomics Clin. Appl. 3(5), 574-583 (2009).
136. Manaka H, Kato T, Kurita K et al. Marked increase in cerebrospinal fluid ubiquitin in Creutzfeldt-Jakob disease. Neurosci. Lett. 139(1), 47-49 (1992).
137. Herbst A, McIlwain S, Schmidt JJ et al. Prion disease diagnosis by proteomic profiling. J. Proteome Res. 8(2), 1030-1036 (2009).
138. Steinacker P, Rist W, Swiatek-de-Lange M et al. Ubiquitin as potential cerebrospinal fluid marker of Creutzfeldt-Jakob disease. Proteomics 10(1), 81-89 (2010).
139. Baker CA, Manuelidis L. Unique inflammatory RNA profiles of microglia in Creutzfeldt-Jakob disease. Proc. Natl Acad. Sci. USA 100(2), 675-679 (2003).
140. Sorensen G, Medina S, Parchaliuk D et al. Comprehensive transcriptional profiling of prion infection in mouse models reveals networks of responsive genes. BMC Genomics 9, 114 (2008). (Pubitemid 351524588)
141. Xiang W, Windl O, Wunsch G et al. Identification of differentially expressed genes in scrapie-infected mouse brains by using global gene expression technology. J. Virol. 78(20), 11051-11060 (2004). (Pubitemid 39299645)
142. Brown AR, Webb J, Rebus S, Williams A, Fazakerley JK. Identification of up-regulated genes by array analysis in scrapie-infected mouse brains. Neuropathol. Appl. Neurobiol. 30(5), 555-567 (2004). (Pubitemid 39423043)
143. Wadsworth JD, Joiner S, Hill AF et al. Tissue distribution of protease resistant prion protein in variant Creutzfeldt-Jakob disease using a highly sensitive immunoblotting assay. Lancet 358(9277), 171-180 (2001). (Pubitemid 32718539)
144. Lee DC, Stenland CJ, Hartwell RC et al. Monitoring plasma processing steps with a sensitive western blot assay for the detection of the prion protein. J. Virol. Methods 84(1), 77-89 (2000).
145. Zanusso G, Righetti PG, Ferrari S et al. Two-dimensional mapping of three phenotype-associated isoforms of the prion protein in sporadic Creutzfeldt-Jakob disease. Electrophoresis 23(2), 347-355 (2002). (Pubitemid 34157103)
146. Biffiger K, Zwald D, Kaufmann L et al. Validation of a luminescence immunoassay for the detection of PrPSc in brain homogenate. J. Virol. Methods 101(1-2), 79-84 (2002). (Pubitemid 34159110)
147. Safar J, Wille H, Itri V et al. Eight prion strains have PrPSc molecules with different conformations. Nat. Med. 4(10), 1157-1165 (1998). (Pubitemid 28468829)
148. Brown P, Cervenakova L, Diringer H. Blood infectivity and the prospects for a diagnostic screening test in Creutzfeldt-Jakob disease. J. Lab. Clin. Med. 137(1), 5-13 (2001). (Pubitemid 32100170)
149. Onisko B, Dynin I, Requena JR et al. Mass spectrometric detection of attomole amounts of the prion protein by nanoLC/MS/MS. J. Am. Soc. Mass Spectrom. 18(6), 1070-1079 (2007). (Pubitemid 46755582)
150. Alexandrenne C, Hanoux V, Dkhissi F et al. Curative properties of antibodies against prion protein: a comparative in vitro study of monovalent fragments and divalent antibodies. J. Neuroimmunol. 209(1-2), 50-56 (2009).
151. Tsuboi Y, Doh-Ura K, Yamada T. Continuous intraventricular infusion of pentosan polysulfate: clinical trial against prion diseases. Neuropathology 29(5), 632-636 (2009).
152. Boesenberg-Grosse C, Schulz-Schaeffer WJ, Bodemer M et al. Brain-derived proteins in the CSF: do they correlate with brain pathology in CJD? BMC Neurol. 6, 35 (2006). (Pubitemid 44524378)
153. Vital A, Fernagut PO, Canron MH et al. The nigrostriatal pathway in Creutzfeldt-Jakob disease. J. Neuropathol. Exp. Neurol. 68(7), 809-815 (2009).
154. Xu BJ, Shyr Y, Liang X et al. Proteomic patterns and prediction of glomerulosclerosis and its mechanisms. J. Am. Soc. Nephrol. 16(10), 2967-2975 (2005). (Pubitemid 44743494)
155. Mabbott NA, Bruce ME, Botto M, Walport MJ, Pepys MB. Temporary depletion of complement component C3 or genetic deficiency of C1q significantly delays onset of scrapie. Nat. Med. 7(4), 485-487 (2001). (Pubitemid 32298553)
156. Ishii T, Haga S, Yagishita S, Tateishi J. The presence of complements in amyloid plaques of Creutzfeldt-Jakob disease and Gerstmann-Straussler-Scheinker disease. Appl. Pathol. 2(6), 370-379 (1984). (Pubitemid 16028901)
157. Klein MA, Kaeser PS, Schwarz P et al. Complement facilitates early prion pathogenesis. Nat. Med. 7(4), 488-492 (2001). (Pubitemid 32298554)
158. Schmidt H, Otto M, Niedmann P et al. CSF lactate dehydrogenase activity in patients with Creutzfeldt-Jakob disease exceeds that in other dementias. Dement. Geriatr. Cogn. Disord. 17(3), 204-206 (2004). (Pubitemid 38339748)